tetano
Editor, Senior Moderator
J Med Virol. 2020 May 8. doi: 10.1002/jmv.25989. [Epub ahead of print]
A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex.
Zeng F[SUP]1[/SUP], Dai C[SUP]2[/SUP], Cai P[SUP]1[/SUP], Wang J[SUP]1[/SUP], Xu L[SUP]1[/SUP], Li J[SUP]1[/SUP], Hu G[SUP]1[/SUP], Wang Z[SUP]3[/SUP], Zheng F[SUP]2[/SUP], Wang L[SUP]1[/SUP].
Author information
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China at the end of 2019 has spread throughout the world and caused many thousands of deaths. Previous study reported a higher severe status rate and mortality rate in male patients in China. However, the reason underlying this difference has not been reported. Convalescent plasma containing high level of SARS-CoV-2 IgG antibody has been used in clinical therapy and achieved good effects in China. In this study, to compare the differences of SARS-CoV-2 IgG antibody between male and female patients, a total number of 331 patients confirmed SARS-CoV-2 infection were enrolled. Serum of these patients were collected during hospitalization and detected for SARS-CoV-2 IgG antibody. Our data showed that the concentration of IgG antibody in mild, general and recovering patients showed no difference between male and female patients. In severe status, compared with male patients, there were more female patients having a relatively high concentration of serum SARS-CoV-2 IgG antibody. In addition, the generation of IgG antibody in female patients was stronger than male patients in disease early phase. Our study identified a discrepancy in SARS-CoV-2 IgG antibody level in male and female patients, which may be a potential cause leading to different outcome of COVID-19 between sex. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19 patients; SARS-CoV-2 IgG antibody; sexual discrepancy
PMID:32383183DOI:10.1002/jmv.25989
A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex.
Zeng F[SUP]1[/SUP], Dai C[SUP]2[/SUP], Cai P[SUP]1[/SUP], Wang J[SUP]1[/SUP], Xu L[SUP]1[/SUP], Li J[SUP]1[/SUP], Hu G[SUP]1[/SUP], Wang Z[SUP]3[/SUP], Zheng F[SUP]2[/SUP], Wang L[SUP]1[/SUP].
Author information
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China at the end of 2019 has spread throughout the world and caused many thousands of deaths. Previous study reported a higher severe status rate and mortality rate in male patients in China. However, the reason underlying this difference has not been reported. Convalescent plasma containing high level of SARS-CoV-2 IgG antibody has been used in clinical therapy and achieved good effects in China. In this study, to compare the differences of SARS-CoV-2 IgG antibody between male and female patients, a total number of 331 patients confirmed SARS-CoV-2 infection were enrolled. Serum of these patients were collected during hospitalization and detected for SARS-CoV-2 IgG antibody. Our data showed that the concentration of IgG antibody in mild, general and recovering patients showed no difference between male and female patients. In severe status, compared with male patients, there were more female patients having a relatively high concentration of serum SARS-CoV-2 IgG antibody. In addition, the generation of IgG antibody in female patients was stronger than male patients in disease early phase. Our study identified a discrepancy in SARS-CoV-2 IgG antibody level in male and female patients, which may be a potential cause leading to different outcome of COVID-19 between sex. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19 patients; SARS-CoV-2 IgG antibody; sexual discrepancy
PMID:32383183DOI:10.1002/jmv.25989